Thijs, Roland D.
Ryvlin, Philippe
Surges, Rainer
Article History
Accepted: 24 September 2021
First Online: 29 October 2021
Competing interests
: R.D.T. reports lecture and consultancy fees from Medtronic, Union Chimique Belge (UCB), Theravarance, Novartis, Zogenix and Arvelle and grants from the Dutch National Epilepsy Fund, Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie, the AC Thomson Foundation, Medtronic, NewLife Wearables and The Netherlands Organisation for Health Research and Development (grant no. 843002707). P.R. reports lecture and consultancy fees from Arvelle, Eisai, LivaNova, Medtronic, Novartis and UCB Pharma and research grants from the Hassler Foundation (Switzerland), the Swiss National Science Foundation and the European Commission. R.S. reports lecture and consultancy fees from Arvelle, Bial, Angelini, Desitin, Eisai, LivaNova, Novartis, UCB Pharma and UnEEG and research grants from the Boll foundation (Kerpen, Germany), BONFOR research funding (Medical Faculty, University of Bonn, Germany), the Federal Ministry of Education and Research (Germany), the Federal Ministry of Health (Germany), and the Verein zur Förderung der Epilepsieforschung e.V. (Bonn, Germany).